Federico Pulido

7.5k total citations · 1 hit paper
149 papers, 3.5k citations indexed

About

Federico Pulido is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Federico Pulido has authored 149 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Infectious Diseases, 73 papers in Virology and 45 papers in Epidemiology. Recurrent topics in Federico Pulido's work include HIV/AIDS drug development and treatment (87 papers), HIV Research and Treatment (72 papers) and HIV/AIDS Research and Interventions (54 papers). Federico Pulido is often cited by papers focused on HIV/AIDS drug development and treatment (87 papers), HIV Research and Treatment (72 papers) and HIV/AIDS Research and Interventions (54 papers). Federico Pulido collaborates with scholars based in Spain, United States and United Kingdom. Federico Pulido's co-authors include Rafael Rubio, José Ramón Arribas, Rafaël Delgado, Sherene Min, David M. Margolis, Daniel Podzamczer, Juan González‐García, Alberto Arranz, Chloe Orkin and W. D. Hardy and has published in prestigious journals such as The Lancet, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Federico Pulido

141 papers receiving 3.4k citations

Hit Papers

Once-daily dolutegravir versus raltegravir in antiretrovi... 2013 2026 2017 2021 2013 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
    2013 404 citations François Raffi, Anita Rachlis et al. The Lancet profile →

Peers

Federico Pulido
Josep M. Llibre Spain
Babafemi Taiwo United States
José L. Casado Spain
Daniel J. Skiest United States
Jeffrey L. Lennox United States
Elisa de Lazzari Spain
Princy Kumar United States
Mauro Schechter Brazil
Thanyawee Puthanakit Thailand
Rohan Hazra United States
Josep M. Llibre Spain
Federico Pulido
Citations per year, relative to Federico Pulido Federico Pulido (= 1×) peers Josep M. Llibre

Countries citing papers authored by Federico Pulido

Since Specialization
Citations

This map shows the geographic impact of Federico Pulido's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Pulido with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Pulido more than expected).

Fields of papers citing papers by Federico Pulido

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Pulido. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Pulido. The network helps show where Federico Pulido may publish in the future.

Co-authorship network of co-authors of Federico Pulido

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Pulido. A scholar is included among the top collaborators of Federico Pulido based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Pulido. Federico Pulido is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
González, Víctor Quirós, Rafael Rubio, Federico Pulido, et al.. (2023). Healthcare outcomes in patients with HIV infection at a tertiary hospital during the COVID-19 pandemic. Enfermedades infecciosas y microbiologia clinica (English ed ). 41(3). 149–154. 2 indexed citations
3.
Buckley, Rosa de Miguel, Rocío Montejano, María Jiménez-González, et al.. (2022). Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance. Open Forum Infectious Diseases. 9(11). ofac610–ofac610. 7 indexed citations
4.
Cabello, Alfonso, Luz Martı́n-Carbonero, Jesús Sanz, et al.. (2022). 48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort. PLoS ONE. 17(11). e0277606–e0277606. 10 indexed citations
5.
Bisbal, Otilia, et al.. (2021). Incidence and Severity of SARS-CoV-2 Infection in HIV-Infected Individuals During the First Year of the Pandemic. JAIDS Journal of Acquired Immune Deficiency Syndromes. 89(5). 511–518. 8 indexed citations
6.
Kerrigan, Deanna, Miranda Murray, Tahilin Sanchez Karver, et al.. (2020). Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial. AIDS Research and Human Retroviruses. 37(3). 207–213. 4 indexed citations
7.
Bayón, Carmen, Asunción Hernando, Félix Gutiérrez, et al.. (2016). Toward a comprehensive care of HIV patients: finding a strategy to detect depression in a Spanish HIV cohort. AIDS Care. 28(7). 834–841. 3 indexed citations
8.
Llibre, Josep M., Federico Pulido, Féderico García, et al.. (2015). Genetic barrier to resistance for dolutegravir.. PubMed. 17(1). 56–64. 82 indexed citations
9.
10.
Bernardino, José Ignacio, Federico Pulido, Estebán Martínez, et al.. (2013). Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. Journal of Antimicrobial Chemotherapy. 68(6). 1373–1381. 10 indexed citations
11.
Raffi, François, Anita Rachlis, Hans‐Jürgen Stellbrink, et al.. (2013). Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. The Lancet. 381(9868). 735–743. 404 indexed citations breakdown →
12.
Blanco, José Ramón, Inmaculada Jarrín, Juan Berenguer, et al.. (2012). Definition of Advanced Age in HIV Infection: Looking for an Age Cut-Off. AIDS Research and Human Retroviruses. 28(9). 1000–1006. 68 indexed citations
13.
Pérez‐Molina, José A. & Federico Pulido. (2012). Evaluación del impacto del nuevo marco legal sanitario sobre los inmigrantes en situación irregular en España: el caso de la infección por el virus de la inmunodeficiencia humana. Enfermedades Infecciosas y Microbiología Clínica. 30(8). 472–478. 32 indexed citations
14.
Llenas‐García, Jara, Rafael Rubio, Asunción Hernando, et al.. (2012). Características clínico-epidemiológicas de los pacientes inmigrantes con infección por el VIH: estudio de 371 casos. Enfermedades Infecciosas y Microbiología Clínica. 30(8). 441–451. 12 indexed citations
15.
Pulido, Federico, Mauro Schechter, Eugènia Negredo, et al.. (2011). Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis. PLoS ONE. 6(7). e22003–e22003. 71 indexed citations
16.
Pulido, Federico, et al.. (2010). Boosted protease inhibitor monotherapy. What have we learnt after seven years of research?. PubMed. 12(3). 127–34. 7 indexed citations
17.
Pulido, Federico, Rafaël Delgado, Ignacio Valero, et al.. (2008). Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Journal of Antimicrobial Chemotherapy. 61(6). 1359–1361. 37 indexed citations
18.
Escribano, M., et al.. (2004). Manejo de sistemas ovinos de dehesas: Análisis de la carga ganadera y de sus resultados económicos en relación a la dimensión de la explotación. 5(2). 30–35. 1 indexed citations
19.
Hernández, Felipe, Pilar Escribano Subías, Maite Velázquez Martín, et al.. (2001). Disfunción diastólica en la infección por el virus de la inmunodeficiencia humana. Revista Española de Cardiología. 54(10). 1183–1189. 4 indexed citations
20.
Laguna, Fernando Ballester, Rogelio López‐Vélez, Federico Pulido, et al.. (1999). Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS. 13(9). 1063–1069. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Josep M. Llibre Breakdown of academic impact, for papers by Babafemi Taiwo Breakdown of academic impact, for papers by José L. Casado Breakdown of academic impact, for papers by Daniel J. Skiest Breakdown of academic impact, for papers by Jeffrey L. Lennox Breakdown of academic impact, for papers by Elisa de Lazzari Breakdown of academic impact, for papers by Princy Kumar Breakdown of academic impact, for papers by Mauro Schechter Breakdown of academic impact, for papers by Thanyawee Puthanakit Breakdown of academic impact, for papers by Rohan Hazra
Rankless by CCL
2026